Revised deal with Depomed gives Santarus more control over US marketing of Glumetza
This article was originally published in Scrip
Executive Summary
Depomed and partner Santarus have built upon a 2008 deal covering the US commercialisation of Depomed's type 2 diabetes treatment, Glumetza (metformin HCl) extended-release tablets. Santarus previously was entitled solely to promotional rights, but will be assuming broad US responsibilities, including those related to manufacturing and regulations, and will be begin recording US sales on 1 September. At the same time, Santarus hopes to halt losing sales to generic metformin with E-vouchers given at the point of pharmacy purchase enabling certain patients to make only a $10 co-payment (similar to the cost of a generic), compared to a $60 co-payment.